- Home
- DCTH vs VYGR Comparison
DCTH vs VYGR Comparison
Compare DCTH & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- VYGR
- Stock Information
- Founded
- DCTH 1988
- VYGR 2013
- Country
- DCTH United States
- VYGR United States
- Employees
- DCTH N/A
- VYGR N/A
- Industry
- DCTH Medical/Dental Instruments
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- DCTH Health Care
- VYGR Health Care
- Exchange
- DCTH Nasdaq
- VYGR Nasdaq
- Market Cap
- DCTH 352.0M
- VYGR 342.5M
- IPO Year
- DCTH N/A
- VYGR 2015
- Fundamental
- Price
- DCTH $11.69
- VYGR $5.81
- Analyst Decision
- DCTH Strong Buy
- VYGR Strong Buy
- Analyst Count
- DCTH 4
- VYGR 9
- Target Price
- DCTH $21.50
- VYGR $16.44
- AVG Volume (30 Days)
- DCTH 346.0K
- VYGR 472.1K
- Earning Date
- DCTH 11-08-2024
- VYGR 11-12-2024
- Dividend Yield
- DCTH N/A
- VYGR N/A
- EPS Growth
- DCTH N/A
- VYGR N/A
- EPS
- DCTH N/A
- VYGR 0.47
- Revenue
- DCTH $22,644,000.00
- VYGR $163,784,000.00
- Revenue This Year
- DCTH $1,605.13
- VYGR N/A
- Revenue Next Year
- DCTH $111.67
- VYGR N/A
- P/E Ratio
- DCTH N/A
- VYGR $12.39
- Revenue Growth
- DCTH 945.91
- VYGR 3.40
- 52 Week Low
- DCTH $3.70
- VYGR $5.19
- 52 Week High
- DCTH $13.30
- VYGR $11.72
- Technical
- Relative Strength Index (RSI)
- DCTH 51.68
- VYGR 40.10
- Support Level
- DCTH $10.75
- VYGR $5.60
- Resistance Level
- DCTH $11.59
- VYGR $6.55
- Average True Range (ATR)
- DCTH 0.70
- VYGR 0.32
- MACD
- DCTH -0.11
- VYGR -0.05
- Stochastic Oscillator
- DCTH 24.56
- VYGR 11.22
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.